Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

被引：0
|
作者：
Lin, C-C. [1 ]
Schneider, R. [2 ]
Gutierrez, M. [3 ]
Shen, L. [4 ]
Chung, K. [5 ]
Doroshow, D. B. [6 ]
Gao, B. [7 ,8 ]
Millward, M. [9 ]
Hsieh, C-Y. [10 ]
Xu, C. [10 ]
Cai, S. X. [10 ]
Tian, Y. E. [10 ]
Liu, L. [10 ]
Shen, C. [10 ]
Tan, Y. [10 ]
He, Y. [10 ]
Zhang, C. [10 ]
Li, L. [11 ]
Ma, M. [10 ]
Xu, L. [10 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Mary Crowley Canc Res, Dept Med Oncol, Dallas, TX USA
[3] Hackensack Univ, Dept Med Oncol, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[4] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
[5] Prisma Hlth Syst Upstate, Clin Res, Inst Translat Oncol Res, Greenville, SC USA
[6] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA
[7] Blacktown Hosp, Haematol & Canc Care Ctr, Blacktown, NSW, Australia
[8] Univ Sydney, Blacktown, NSW, Australia
[9] Linear Clin Res, Oncol, Perth, WA, Australia
[10] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China
[11] IQVIA RDS Shanghai Co Ltd, Beijing Branch, Med, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
632P
引用
收藏
页码：S503 / S504
页数：2
相关论文
共 50 条
  • [1] First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R. E.
    Gutierrez, M.
    Shen, L.
    Gao, B.
    Chung, K.
    Doroshow, D. B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Li, B.
    Tan, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Chen, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S476 - S477
  • [2] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors
    Naing, A.
    Park, J. C.
    Klempner, S. J.
    Khan, S.
    Pearson, P.
    Lufkin, J.
    Keller, P.
    Youssoufian, H.
    DeCillis, A.
    Mazo, I.
    Sommerhalder, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S627 - S628
  • [4] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [5] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [6] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [7] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [8] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
  • [9] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
    Sommerhalder, David
    Hamilton, Erika P.
    Mukohara, Toru
    Yonemori, Kan
    Mita, Monica M.
    Yamashita, Toshinari
    Zheng, Jenny
    Liu, Li
    Maity, Arnab K.
    Mishra, Natasha Homji
    Bogg, Orlaith
    Li, Meng
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
12345